Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study)
Neurology
Données primaires
article
Auteurs : P-M. Llorca, A. Sauvaget, E. Olié, L. Mékaoui, L. Samalin, M. Rothärmel, A-L. Boitez, J. Dupin, C. Wicart, E. Gaudre-Wattinne, H. Lacour, B. Grenier, B. Astruc, B. Falissard, P. de Maricourt
Date de publication : 31 August 2026
Objectives
The ELLIPSE study aimed to describe patient characteristics, treatment patterns, and 12-month outcomes of esketamine in routine clinical practice in France.
Conclusion
This real-world study in patients with treatment-resistant depression, including those with comorbidities/prior suicide attempts, showed clinically relevant improvement from month 2, sustained through 12 months. Dissociative symptoms were the most frequent treatment-related AE.